Replies to post #86861 on Anavex Life Sciences Corp (AVXL)

[makemydaze]

Good post Jimmy667 - I like the way you think. Let Biogen get this Bioverativ spinoff business behind them and then the fireworks may fly.

"Bioverativ is set to host an analyst day Jan. 6, Yee noted. Biogen will have no stake in the spinoff which will focus on developing treatments for hemophilia and rare blood diseases including sickle cell and beta-thalassemia. It will use gene-editing tech from Sangamo.

"Investors appear to be lukewarm on this biz given Biogen choosing to spin it off and also uncertainty on long-term tail for hemophilia given ACE-910 phase 3 data due imminently in December, and gene therapy potential curative solutions."


http://www.investors.com/research/ibd-industry-themes/biogen-likely-to-trim-eps-view-on-hemophilia-spinoff-floundering-ms-unit/